E
Immutep Limited IMMP
$2.01 -$0.02-0.99% NASDAQ
Recommendation
Prev Close
$2.01
Volume
225,994
Avg Vol (90D)
95,467
Market Cap
$293.34M
Dividend & Yield
--
52-Week Range
$1.32 - $2.71
P/E (TTM)
--
EPS (TTM)
-$0.03
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Immutep announces update for TACTI-004 Phase III trial
10/9/2025 - TipRanks Financial Blog
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small ...
10/9/2025 - GuruFocus
Immutep announces update for TACTI-004 Phase III trial
10/9/2025 - The Fly
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
10/9/2025 - Globe Newswire
Immutep Ltd Announces Director's Acquisition of Shares
10/8/2025 - TipRanks Financial Blog
Immutep (IMMP) Launches Phase II Trial for Breast Cancer Treatment
9/22/2025 - GuruFocus
Immutep Announces Research Collaboration with the George Washington University Cancer Center to ...
9/22/2025 - GuruFocus
Immutep enters reseach collaboration with GW University Cancer Center
9/22/2025 - The Fly
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
9/22/2025 - Globe Newswire
Prima BioMed (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average - What's Next?
9/20/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Immutep Ltd (OtherPRRUF)
9/15/2025 - TipRanks Financial Blog
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue ...
9/8/2025 - GuruFocus
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue ...
9/8/2025 - GuruFocus
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
9/8/2025 - Globe Newswire
Immutep's Phase II Trial Data on Soft Tissue Sarcoma to be Presented at CTOS 2025
9/8/2025 - TipRanks Financial Blog
Bell Potter Reaffirms Their Buy Rating on Immutep Ltd (PRRUF)
9/3/2025 - TipRanks Financial Blog
Immutep Reports Increased Losses Amid Rising R&D Costs
9/3/2025 - TipRanks Financial Blog
Immutep Reports Increased Loss Amid Rising R&D Costs
8/29/2025 - TipRanks Financial Blog
Canaccord Genuity Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
8/6/2025 - TipRanks Financial Blog
Immutep (IMMP) Receives FDA Support for Cancer Drug Development
8/5/2025 - GuruFocus
Immutep receives FDA feedback on clinical development of eftilagimod alfa
8/5/2025 - The Fly
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod ...
8/5/2025 - GuruFocus
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS
8/5/2025 - Globe Newswire
Immutep Gains FDA Support for Cancer Therapy Development
8/5/2025 - TipRanks Financial Blog
Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below 50 Day Moving Average - Should You Sell?
8/3/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$3.28M
EBITDA (TTM)
-$40.57M
EBIT (TTM)
-$41.92M
Net Income (TTM)
-$39.55M
Balance Sheet
Total Assets (Q)
$102.92M
Total Debt (Q)
$1.07M
Total Liabilities (Q)
$8.75M
Book Value Per Share (Q)
$0.0645
Cash Flow
Cash from Operations (TTM)
-$40.10M
Cash from Investing (TTM)
-$26.12M
Cash from Financing (TTM)
-$344.40K
Net Change in Cash (TTM)
-$62.20M
Filings
Filing Date
Thursday, August 28, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.11
7-Day Total Return
6.91%
30-Day Total Return
24.84%
60-Day Total Return
18.24%
90-Day Total Return
10.44%
Year to Date Total Return
-9.05%
1-Year Total Return
-2.43%
2-Year Total Return
11.67%
3-Year Total Return
16.18%
5-Year Total Return
18.24%
52-week Low
Apr 07, 2025 - $1.32
52-week High
May 05, 2025 - $2.71
Valuation
Market Cap
$293.34M - Micro Cap
Enterprise Value
$209.43M
Price/Sales (TTM)
913.64
Price/Book (Q)
31.16
Dividends and Shares
Shares Outstanding
1.46K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.immutep.com
Phone Number
61 2 8315 7003
Address
Australia Square
Level 32 - 264 George Street
Sydney, NSW 2000
Country
Australia
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product... more
NASDAQ 10/10/2025 4:00PM Eastern Quotes delayed